FindTrial
Sign In

Research on the Optimization of Clinical Rational Drug Use Management Countermeasures of Edaravone and Rilmenidine Based on the Orientation of Medical Insurance Policies

Research on the Optimization of Clinical Rational Drug Use Management Countermeasures of Edaravone and Rilmenidine Based on the Orientation of Medical Insurance Policies

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122551
Enrollment
Unknown
Registered
2026-04-15
Start date
2026-04-15
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

Observation group:None

Sponsors

Meishan City People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The cases of Edaravone and Rilmenidine being used in hospitals in 2024

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

MeasureTime frame
Inappropriate medication use rate;—

Countries

China

Contacts

Public ContactZhang Fengjiao

Meishan City People's Hospital

zhangfjms@163.com+86 15183318126

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026